What is William Blair’s Estimate for NMRA Q1 Earnings?

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Equities research analysts at William Blair issued their Q1 2026 earnings estimates for shares of Neumora Therapeutics in a research report issued on Monday, March 3rd. William Blair analyst M. Minter anticipates that the company will post earnings of ($0.44) per share for the quarter. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.61) per share. William Blair also issued estimates for Neumora Therapeutics’ Q2 2026 earnings at ($0.42) EPS, Q3 2026 earnings at ($0.43) EPS and Q4 2026 earnings at ($0.45) EPS.

NMRA has been the subject of several other reports. HC Wainwright decreased their target price on shares of Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday. Royal Bank of Canada reiterated a “sector perform” rating and issued a $4.00 price objective on shares of Neumora Therapeutics in a report on Tuesday. Bank of America lowered their target price on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $5.00 price target on shares of Neumora Therapeutics in a research report on Tuesday. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, Neumora Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $11.50.

Neumora Therapeutics Stock Performance

NASDAQ:NMRA opened at $1.43 on Wednesday. The company has a market capitalization of $231.03 million, a P/E ratio of -0.76 and a beta of 2.50. The stock’s 50 day moving average price is $2.83 and its 200 day moving average price is $8.76. Neumora Therapeutics has a 52 week low of $1.35 and a 52 week high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA) last issued its earnings results on Thursday, March 6th. The company reported ($0.37) EPS for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.09.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Windmill Hill Asset Management Ltd increased its position in Neumora Therapeutics by 299.6% during the fourth quarter. Windmill Hill Asset Management Ltd now owns 104,373 shares of the company’s stock worth $1,106,000 after acquiring an additional 78,252 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Neumora Therapeutics during the fourth quarter worth $770,000. Wexford Capital LP increased its holdings in Neumora Therapeutics by 15.7% in the 4th quarter. Wexford Capital LP now owns 252,122 shares of the company’s stock valued at $2,672,000 after buying an additional 34,243 shares during the period. Toronto Dominion Bank acquired a new position in shares of Neumora Therapeutics in the 4th quarter valued at $364,000. Finally, Stempoint Capital LP bought a new position in shares of Neumora Therapeutics during the 4th quarter worth about $4,538,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.